Nama's AI scorecard currently rates Nurix Therapeutics Buy (7.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NRIX's P/E ratio?

Nurix Therapeutics trades at a trailing price-to-earnings ratio of 6.6.

When does NRIX report earnings?

Nurix Therapeutics's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $1.51.

What is the NRIX price target?

The median analyst price target from 14 analysts is $34.50, with a range of $20.00 – $41.00.

Is NRIX Shariah compliant?

Nama's AAOIFI-style screen reads Nurix Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Nurix Therapeutics (NRIX)

Healthcare · Biotechnology · NASDAQ

Nurix Therapeutics (NRIX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.67B, a trailing price-to-earnings ratio of 6.6 and a free-cash-flow yield of -19.9%. Over the most recent reported fiscal year, revenue grew 54.0%. Nama's AI scorecard rates it Buy, 7.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.3/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +81.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-55.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.67B
Trailing P/E	6.6
Price / book	1.7
Price / sales	2.4
FCF yield	-19.9%
Dividend yield	—
Gross margin	52.4%
Operating margin	—
Net margin	42.0%
Revenue growth (YoY)	+54.0%
Revenue growth (3-yr annual)	+29.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

NRIX earnings

Next report: Jan 28, 2027 (Q4 2026, EPS estimate $1.51). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 11, 2026	$4.73	$5.02	-5.8%	$673.06M
Q2 2026	Jul 9, 2026	-$0.81	-$0.72	-12.5%	$9.04M
Q1 2026	Apr 8, 2026	-$0.79	-$0.76	-4.0%	$6.25M
Q4 2025	Jan 28, 2026	-$0.82	-$0.92	+10.9%	$13.58M

NRIX analyst price target

Median target $34.50 from 14 analysts, ranging $20.00 – $41.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live NRIX data on Nama Insights →

NRIX FAQ

Is NRIX a buy?: Nama's AI scorecard currently rates Nurix Therapeutics Buy (7.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NRIX's P/E ratio?: Nurix Therapeutics trades at a trailing price-to-earnings ratio of 6.6.
When does NRIX report earnings?: Nurix Therapeutics's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $1.51.
What is the NRIX price target?: The median analyst price target from 14 analysts is $34.50, with a range of $20.00 – $41.00.
Is NRIX Shariah compliant?: Nama's AAOIFI-style screen reads Nurix Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.